Ghanaian vaccine and pharmaceutical manufacturers are gaining potential access to a continental market of 1.4 billion people through Africa’s pooled procurement mechanism.
The Ghanaian government and Africa CDC have signed a memorandum allowing Ghana to participate in the African Pooled Procurement Mechanism. The system aims to aggregate demand from African countries in order to create a more predictable market for manufacturers on the continent.
For Ghanaian pharmaceutical companies, the opportunity is significant because the domestic market of approximately 33 million people has historically limited the scale required to justify major manufacturing investments.
A Regional Market to Support Industrial Investment
Ghana plans to produce vaccines against tetanus and diphtheria as well as tetanus antiserum in 2026. The country has already been producing antivenom serum since 2025. Authorities also intend to introduce an Advance Purchase Commitment system designed to reduce the commercial risk associated with pharmaceutical manufacturing investments.
The Food and Drugs Authority will retain responsibility for marketing authorisations, quality controls and batch release. The initiative is expected to strengthen Ghana’s position as a potential pharmaceutical manufacturing hub for Africa.
